RBD-SpyCatcher-mi3 vaccine construct could be a promising candidate for broad protection against SARS-CoV-2 variants, advocating for further clinical testing.
Potent Neutralisation of Sars-CoV-2 Including Variants of Concern by Vaccines Presenting the Receptor-binding Domain Multivalently from Nanoscaffolds
